Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
The University of Texas Health Science Center at San Antonio
CBD is a non-psychoactive, non-addictive compound of cannabis that has shown analgesic and anti-inflammatory properties. Epidiolex is the only FDA-approved oral CBD solution and will be the drug of choice in this study.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Healthy adults 18-75 years old, ASA I or II
permanent tooth with moderate to severe odontogenic pain, i.e. ≥30 on a 100mm VAS,
clinical pulpal diagnosis of irreversible pulpitis or pulpal necrosis, and periapical diagnosis of symptomatic apical periodontitis
test negative for recent cannabis use and/or other drugs of abuse including alcohol (urine tests collected at screening visit), and participant
able to understand the forms (English or Spanish) and provide informed written consent.
You may not be if
ASA Class III or IV
patients with hepatic impairment
pregnant or lactating women
Patients on drugs metabolized by enzymes that also metabolize CBD (e.g. clobazam, diazepam, topiramate, warfarin)
self-reported prior experience inhaling cannabis (either via smoking or vaporization), use of opioids in the month prior to screening/treatment visit, and/or NSAIDS or acetaminophen 6 hours prior to treatment
